Indomethacin considered one of the most commonly used NSAIDs to treat pain and inflammation among elder patients. Ironically, it has high risk of gastrointestinal complication, ulceration and in some cases perforation. Pinocembrin is one of the natural flavonoid present in honey and posses anti-inflammatory, anti-oxidant, and antiapoptotic activities. The present study was conducted to investigate the possible therapeutic effects of Pinocembrin on indomethacin induced gastric ulcer model in rats. Animals either pre-treated with pinocembrin 50mg/kg for 3 days before ulcer induction with one single dose of indomethacin (48 mg/kg) orally or post-treated with pinocembrin 50mg/kg/3 days and 50mg/kg/5days after 1 hr of ulcer induction with same dose of indomethacin. The therapeutic effects were determined via measuring oxidative stress markers as well as histopathological investigation. Pinocembrin protected gastric tissues which was confirmed histopathologically. It also increased levels of CAT, GSH and decreased levels of MDA enzymes. In conclusion, these findings show that pinocembrin have therapeutic effects in indomethacin induced gastric ulcer.
Introduction
In the digestive system, peptic ulcer denote one of the most critical diseases which caused by disturbance in the protection of stomach mucosa against gastric acid (Bucciarelli et al., 2010; Sa'nchez-Mendoza et al., 2011). Nowadays the risk of gastric attacks is significantly increased due to exposure of human to many noxious agents such as alcohol consumption, Heliobacter pylori infection and use of nonsteroidal anti-inflammatory drugs (NSAIDs) and it is estimated that nearly 20% of the world population suffer from peptic ulcer ( Pinocembrin (5,7-dihydroxyflavanone) is one of the primary flavonoids that has been identified in honey and has been studied in many diseases such as stroke, Alzheimer, cardiovascular, and atherosclerosis in vitro and in vivo (Lan et al., 2015) .
In an in vitro study, (Soromou et al.,2012) demonstrated that pinocembrin inhibits proinflammatory cytokines in the murine macrophage and endotoxin-induced acute lung injury model, partly by decreasing the levels of MAPK and NF-κB activation. In vivo, pretreatment with pinocembrin (50 mg/kg, IP) significantly lowered LPS-induced pro-inflammatory cytokines TNF-α, IL-1β and IL-6 production in a time-dependent manner, indicating that the protective role may be attributable, to inhibition of pro-inflammatory cytokine release. (Soromou et al., 2014) also found that pretreatment with pinocembrin (20 or 50 mg/kg, IP) reduced mortality from LPSinduced endotoxin shock in mice, however, post-treatment with pinocembrin failed to exert any therapeutic effects.
The aim of this study were to evalute the potential Therapeutic effects of Pinocembrin on indomethacin induced gastric ulcer model in rats and the possible underlying mechanisms through studying the anti-inflammatory, and anti-oxidant properties.
Material and methods

Material
Pinocembrin (PIN) was purchased from Xi'an natural-field bio-technique Co, Shanghai, China. Indomethacin (IND) was purchased from Nile Co. for Pharmaceutical and Chemical Industries, Egypt. Used chemicals were obtained from Indomedix Co., and Sigma pharmaceutical industries Cairo, Egypt. All chemicals were of the highest purity grade commercially available.
Animals
Male spargue-Dawly rats (180-200 gm) were obtained from Nile Co. for Pharmaceutical and Chemical Industries, Cairo, Egypt. Animals were provided with balanced laboratory diet and tap water ad libitum for 1 week before assignment to the experimental protocol. All animals were deprived of food 24 hr before ulcer induction with free access to tap water. Experimental procedures were conducted in accordance with the international ethical guidelines for investigations in laboratory animals and were approved by the Research Ethical Committee of Faculty of Pharmacy, Ain shams University (Cairo, Egypt).
Method Experimental design
Animals were randomly divided into five groups (six animals each). The first group received the vehicle only and served as the control group. The second group received single oral dose of IND 48 mg/kg (Krishnendu et al., 2015), to induce gastric ulcer. The third was given pinocembrin 50mg/kg/day, for 3 days perior to ulcer induction. The fourth and fifth groups were given pinocembrin 50mg/kg/day, for 3 consecutive days and 5 days respectively 1 hr after ulcer induction. Pinocembrin doses were determined based on previous studies reporting its properties (Lan et al., 2015). Rats were sacrificed 6 hrs later and stomach tissues were dissected out, and washed with ice-cold saline. Gastric tissue specimens of each group were fixed in 10% formalin for histopathological examination.
Assessment of oxidative stress markers
Catalase enzyme (CAT), reduced glutathione (GSH) and malondialdehyde (MDA) levels were determined colorimetrically by using Biodiagnostics kits (Cairo, Egypt). All procedures were performed according to the manufacturer's instructions.
Histopathological & mucin content examination
Stomach sections from different groups were sliced and fixed in 10% formalin then, embedded in paraffin blocks. Slices of 4 μm thickness were stained with either hematoxylin & eosin (H&E) stain in case of histopathological examination, or alcian blue stain for mucin detection using light microscope (Bancroft et al, 1996 ).
Statistical analysis
Data are presented as mean ± SD. Multiple comparisons were performed using one-way ANOVA followed by Tukey-Kramer test for post hoc analysis. All statistical analyses were performed , while the graphs were drawn using a prism computer program (GraphPad software Inc., La Jolla, CA, USA) with p value less than or equal to 0.05 represent statistical significance.
Results
oxidative stress markers. CAT assessment:
Catalase levels were significantly reduced in indomethacin treated group by 38.6% as compared to control values. Interestingly, pinocembrin 50mg/kg pretreatment significantly increased CAT level by 85.4% as compared to 80.8% increase in case of pinocembrin 50mg/kg/3days treated group. pinocembrin 50mg/kg/5 days showed 93.7% increase in CAT level. The longest duration of pinocembrin treatment (50mg/kg/5day) showed the best antioxidant effect when compared to groups. (Fig.1 ) GSH assessment: GSH level was markedly decreased in indomethacin treated rats by 40.2% as compared to control values. Rats pretreated with pinocembrin 50mg/kg significantly decreased GSH level by 89.4% as compared to 91.3% increase in case of pinocembrin 50mg/kg/3days treated group. pinocembrin 50mg/kg/5 days showed 95.1% increase in GSH level. (Fig.2 Statistically significant from the control or the indomethacin group, respectively at P< 0.05 using ANOVA followed by Tukey-Kramer as a post-hoc test.
MDA assessment:
MDA level was markedly increased in indomethacin treated rats by 187.5% compared to control values. Rats pretreated with pinocembrin 50mg/kg significantly decreased MDA level by 114.3% as compared to 85.2% increase in case of pinocembrin 50mg/kg/3days treated group. pinocembrin 50mg/kg/5 days showed 92.6% increase in MDA level. (Fig.3)   Fig. (3) : Effect of pinocembrin on gastric tissue level of malondialdehyde in indomethacin-induced gastric ulcer model as percentage of control. a or b: Statistically significant from the control or the indomethacin group, respectively at P< 0.05 using ANOVA followed by Tukey-Kramer as a post-hoc test. Histopathology Figure 4 shows the effects of the different treatment groups on the histological structure of stomach. No histopathological alterations were recorded in the control group (Fig.  4A) . Focal ulceration and pigmentation of the tips of the mucosa were detected associated with massive numbers of inflammatory cells infiltration and congestion in the blood of the submucosa in gastric tissues taken from indomethacin-treated group (Fig. 4B) . Animals pretreated by pinocembrin 50mg/kg/ 3days showed no histopathological alternation (Fig. 4C) . Gastric tissues in pinocembrin 50mg/kg/ 3days treated group showed blood congestion in the submucosa (Fig. 4D) . Animals treated with pinocembrin 50 mg/kg for 5 days showed no histopathological change (Fig. 4E) . 
A C B D E
Mucin content
Photomicrographs from control group (Fig. 5A) showed alcian blue moderate positive reaction with mucin appeared as blue color in mucosal layer while indomethacin-treated group showed alcian blue negative reaction in the area of ulceration of the mucosa (Fig. 5B) . All other groups showed alcian blue severe positive reaction in mucosal layer (Fig.5C&5D) except pinocembrin 50mg/kg/ 5 days posttreated group (Fig. 5E ) which showed moderate reaction with alcian blue in mucosal layer. (Fig. 5)   Fig. (5) : The severity of Alcian Blue Mucopolysaccharide detection in mucosal layer of stomach in different experimental groups. Control group (A) showed moderate reaction (++) while indomethacin treated group (B) showed mild reaction which indicate reduced mucin secretion (+). Pinocembrin 50mg/kg pretreated group and pinocembrin 50mg/kg/3 days post-treated group (C and D) respectively, showed sever reaction(+++) while pinocembrin 50mg/kg/5 days post-treated group (E) showed moderate alcian blue reaction (++) in mucosal layer.
Discussion
Gastric ulcer therapy nowadays represent one of the challenges facing medicine since currently marketed drugs showed limited efficacy and severe side effects (Mota et  al., 2009) . Therefore, the development of anti-ulcer compound from natural resources is still a target in recent medicinal research. The present study was designed to investigate C A B
D E
the potential therapeutic effects of pinocembrin on indomethacin-induced gastric ulcer in rats as well as the possible underlying mechanisms through studying the antiinflammatory, and anti-oxidant properties.
It showed that administration of pinocembrin 50mg/kg for 3 days prior to ulcer induction protected the stomach from the damage caused by indomethacin which was confirmed by histopathological assessment and oxidative stress markers determination. The histopathological findings demonstrated that the administration of pinocembrin 50mg/kg for 5 days after ulcer induction showed complete healing effect on gastric tissue which was further confirmed by mucin content assessment. Treatment with same dose of pinocembrin for 3 days showed blood congestion in submucosa with intact mucosa which was confirmed by severe reaction with alcian blue stain in the mucosal layer . Pinocembrin also induced antioxidant effects, it increased gastric tissue levels of catalase, reduced glutathione and decreased levels of malondialdehyde in a time dependent manner. This was in line with previous studies concerning pinocembrin antiinflammatory, and anti-oxidant properties (Lan et al, 2015). Pinocembrin's pharmacological activities has been well investigated, for its anti-inflammatory, antiapoptotic, antioxidant and anticancer effects especially in Alzheimer's disease, cardiovascular diseases, and atherosclerosis. Studies showed that pinocembrin (10 mg/kg, i.v.) could reduce brain swelling; and alleviate neuronal apoptosis In summary, the present study demonstrated that pre-treatment with pinocembrin showed a protective capacity and markedly attenuated indomethacininduced oxidative stress and gastric tissue damage. pinocembrin post-treatment showed antioxidant activity which was increased in time dependent manner. This was evident by the significant increase in CAT, and GSH levels and decrease in MDA level in gastric tissue samples of both treatment groups as compared to indomethacin-treated group. The previous results suggest that pinocembrin might represent a promising pharmacological drug in gastric ulcer treatment with potential antioxidant and antiinflammatory properties.
Conclusion
In conclusion, the present study provides an evidence for the therapeutic effects of pinocembrin on indomethacin-induced gastric ulcer in which it acts as gastroprotective agent prior to ulcer or as a treatment after ulcer induction. Further studies may be done to determine the optimum therapeutic dose of pinocembrin which poses the highest effect and the lowest side effects . 
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